Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology

Galapagos to pay up to $27 million in upfront and preclinical milestone payments to BridGene

08-Jan-2024 - Galapagos NV announced that it has entered into a strategic collaboration and licensing agreement with BridGene Biosciences, Inc. (“Bridgene”), a biotechnology company that uses proprietary chemoproteomics technology to discover novel small molecule drug candidates. Through this collaboration, ...

Servier and Galapagos initiate strategic alliance for innovative treatments in oncology

Joint discovery and development of novel small molecule therapies for cancer

11-Oct-2011 - Servier and Galapagos NV announced that they have entered into a multi-year strategic alliance to develop new cancer therapies. The alliance builds on a combination of novel Galapagos and Servier targets in oncology. Galapagos will be responsible for the discovery and development of new ...

Galapagos delivers validated oncology targets to Janssen

26-Apr-2011 - Galapagos NV announced that its BioFocus service division has delivered a panel of validated oncology targets in its collaboration with Janssen Research & Development, a division of Janssen Pharmaceutica N.V. (Janssen). Per the agreement, Janssen retains full rights to discover, develop and ...

Galapagos discontinues Phase II trial for GLPG0259, focuses resources on other rheumatoid arthritis programs

19-Apr-2011 - Galapagos NV announced that it will discontinue its Phase II clinical trial for GLPG0259 in rheumatoid arthritis. This decision is based on the outcome of a planned interim analysis which did not support the continuation of GLPG0259's development for rheumatoid arthritis. An Interim Review ...

Galapagos and the National Cancer Institute sign compound management agreement

13-Oct-2010 - Galapagos NV announced that the Compound Focus subsidiary of its BioFocus service division has signed an agreement with the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH). Under the terms of the agreement, BioFocus will provide compound management services ...

Galapagos' affiliate Argenta and Janssen Pharmaceutica enter in integrated cancer drug discovery service agreement

05-Oct-2010 - Galapagos NV announced that its affiliate, Argenta Discovery 2009 Limited, has entered into a drug discovery service agreement with Janssen Pharmaceutica N.V. (Janssen), aimed at delivering novel cancer drug candidates. Argenta will provide medicinal chemistry and biology for a number of Janssen ...

BioFocus DPI and Oncodesign forge alliance to provide integrated oncology drug discovery services

28-Jul-2009 - BioFocus DPI and Oncodesign announced that they have joined forces to offer a comprehensive oncology drug discovery service. The alliance combines BioFocus DPI’s target discovery and screening capabilities with Oncodesign’s experimental pharmacological and biomarker expertise in oncology. In ...

Galapagos enters into oncology target discovery collaboration with Janssen Pharmaceutica

04-Jan-2008 - Galapagos NV announced a new two-year target discovery collaboration between Janssen Pharmaceutica and BioFocus DPI, Galapagos' service division, in the field of oncology. BioFocus DPI will apply Galapagos' proprietary adenoviral platform to identify novel drug targets for the development of ...